Currently, inhibiting aberrant mRNA translation in neoplasia involves two treatment modalities: indirectly targeting upstream pathways that converge on the eIF4F complex or directly targeting components of the eIF4F complex. This evidence concerns the gene EIF4G1 and neoplasm.